James Atkinson, MD
Geriatric Medicine · Medford, NJNPI 1881671444
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $602 and has fallen 84.1% since, to $95 in 2025.
Across 139 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$454
- AstraZeneca$373
- AbbVie$312
- Boehringer Ingelheim$260
- Lilly USA, LLC$161
- Pfizer$104
- plus $468 from 19 others
What the payments were for
- Speaking & faculty fees$141%
- Food & beverage$2,11199%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $454 |
| AstraZeneca(2 entities) | 25 | $373 |
| AbbVie | 19 | $312 |
| Boehringer Ingelheim | 17 | $260 |
| Lilly USA, LLC | 10 | $161 |
| Pfizer | 7 | $104 |
| Almatica Pharma LLC | 5 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $63 |
| GSK | 4 | $51 |
| Merck | 2 | $33 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $26 |
| Bayer | 1 | $22 |
| Exact Sciences | 1 | $20 |
| Novartis | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Valinor Pharma, LLC | 1 | $14 |
| Acorda Therapeutics, Inc | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Promius Pharma LLC | 1 | $13 |
| Abbott | 1 | $13 |
| UCB, Inc. | 1 | $12 |
| Althera Pharmaceuticals LLC | 1 | $10 |
How this compares
$2,131 in reported general payments places this provider in the 80th percentile of 165 geriatric medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $136,771 |
| OzempicSemaglutide | 111 | $119,274 |
| JardianceEmpagliflozin | 47 | $62,219 |
| FarxigaDapagliflozin Propanediol | 36 | $38,864 |
| MyrbetriqMirabegron | 38 | $37,962 |
| MounjaroTirzepatide | 22 | $28,247 |
| XareltoRivaroxaban | 22 | $20,706 |
| TradjentaLinagliptin | 22 | $18,985 |
| TrulicityDulaglutide | 11 | $18,439 |
| Candesartan Cilexetil | 64 | $7,640 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,180 |
| Irbesartan | 287 | $7,114 |
| Metoprolol Succinate | 385 | $5,828 |
| Azelastine Hcl | 187 | $5,647 |
| Atorvastatin Calcium | 581 | $5,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $104 | $136,771132 claims |
| Novo NordiskOzempic | $454 | $119,274111 claims |
| Boehringer IngelheimJardiance, Tradjenta | $260 | $81,20369 claims |
| Lilly USA, LLCMounjaro, Trulicity | $161 | $46,68533 claims |
| AstraZenecaFarxiga | $373 | $38,86436 claims |
| Johnson & JohnsonXarelto | $14 | $20,70622 claims |
| GSKBreo Ellipta | $51 | $7,18012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 geriatric medicine providers in New Jersey.
Other geriatric medicine in Medford
- Albert RiddleHaworth$524K
- Gamil MakarClifton$82K
- Joshua Shua HaimManchester$45K
- Pradip ShahWest Caldwell$27K
- Gregorio GuillenPerth Amboy$8K
- Ketankumar VaidyaEdison$8K
- Cheng-An MaoClifton$8K
- Theresa RedlingLivingston$7K
- Sarita RastogiHackensack$7K
- Leslie FeiginDenville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.